Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
September 30, 2026 -16.11M
June 30, 2026 14.01M
March 31, 2026 57.05M
December 31, 2025 30.35M
September 30, 2025 -246.35M
June 30, 2025 54.04M
March 31, 2025 24.81M
December 31, 2024 21.16M
September 30, 2024 -90.82M
June 30, 2024 -8.562M
March 31, 2024 30.05M
December 31, 2023 22.64M
September 30, 2023 -94.96M
June 30, 2023 48.19M
March 31, 2023 18.46M
December 31, 2022 -40.78M
September 30, 2022 -39.70M
June 30, 2022 35.98M
March 31, 2022 72.52M
December 31, 2021 7.248M
September 30, 2021 62.78M
June 30, 2021 13.52M
Date Value
March 31, 2021 -145.71M
December 31, 2020 61.89M
September 30, 2020 34.91M
June 30, 2020 32.86M
March 31, 2020 28.87M
December 31, 2019 -139.13M
September 30, 2019 41.47M
June 30, 2019 46.14M
March 31, 2019 23.54M
December 31, 2018 12.28M
September 30, 2018 -136.47M
June 30, 2018 16.44M
March 31, 2018 20.61M
December 31, 2017 -111.45M
September 30, 2017 6.443M
June 30, 2017 2.983M
March 31, 2017 -8.019M
December 31, 2016
September 30, 2016 1.072M
June 30, 2016 -3.945M
March 31, 2016 -2.341M
December 31, 2015 -0.017M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. -311.74M
Arrowhead Pharmaceuticals, Inc. 203.86M
BioMarin Pharmaceutical, Inc. -306.90M
Cytokinetics, Inc. 67.93M
Exelixis, Inc. -6.708M